Hantz Financial Services Inc. increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12,699.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,091 shares of the medical device company's stock after purchasing an additional 115,184 shares during the period. Hantz Financial Services Inc.'s holdings in DexCom were worth $9,028,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of DXCM. Geode Capital Management LLC grew its stake in shares of DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock valued at $664,056,000 after buying an additional 214,136 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the period. Groupama Asset Managment grew its holdings in shares of DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after buying an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock valued at $183,298,000 after buying an additional 288,381 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Oppenheimer decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company lifted their price objective on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group raised their target price on shares of DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $99.29.
Read Our Latest Stock Report on DexCom
DexCom Stock Performance
DXCM stock traded up $2.07 during trading on Thursday, reaching $88.50. The company had a trading volume of 451,682 shares, compared to its average volume of 3,557,070. The company has a market cap of $34.57 billion, a price-to-earnings ratio of 52.97, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a 50-day simple moving average of $80.22 and a 200-day simple moving average of $76.59.
Insider Activity
In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.30% of the company's stock.
DexCom Company Profile
(
Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
